At AgenTus Therapeutics, we are using advanced mammalian display platform technologies to discover T Cell Receptors (TCRs) and Chimeric Antigen Receptors (CARs) to weaponize adoptive cell therapies to treat cancer.

We are using our leading proprietary TCR platforms to identify, characterize, and optimize TCRs that are directed against tumor-specific antigens, including neo-antigens, to engineer immune effector cells.

Our proprietary receptor discovery platforms enable rapid and efficient identification and optimization of fully human TCRs and CARs to advance as components of living drugs for patients across the world.